BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 02/22/21

BrainStorm Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program FDA recommended generating additional clinical data to meet FDA's BLA requirements PR Newswire NEW YORK , Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics ...

NEW YORK, Jan. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits, CEO will provide a corporate overview presen...

NEW YORK, Jan. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative diseases, today announced that the Israel Patent Office has granted an additional patent titled &#...

NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders. Dear Valued Shareholder, This past year was an extraordinary...

NEW YORK and BOSTON, Dec. 26, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has expanded its autologous cell manufacturing capacity to produce NurOwn...

The FDA has accepted BrainStorm Cell Therapeutics' (NASDAQ: BCLI ) IND application to initiate a Phase 2 clinical trial of NurOwn for the treatment of progressive multiple sclerosis (MS). More news on: BrainStorm Cell Therapeutics Inc., Healthcare stocks news, Stocks on the move, ...

NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has ...

Highlights Preclinical Research and Continued Progress of NurOwn® Platform in ALS Pivotal Trial NEW YORK and PETACH TIKVAH, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell ther...

BrainStorm Cell Therapeutics Inc. (BCLI) Q3 2018 Earnings Conference Call October 29, 2018 8:30 AM ET Executives Joseph Petroziello – Vice President-Scientific and Corporate Communications Chaim Lebovits – President and Chief Executive Officer Eyal Rubin – Ex...

Highlights Scientific Advances and Continued Progress for NurOwn ® in ALS Towards U.S. FDA Approval; Following Successful FDA Pre-IND Meeting, BrainStorm will File an IND for NurOwn ® in a Second Clinical Indication Conference Call and Webcast Today at 8:30am Eastern T...